• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氧化应激和癌胚抗原相关细胞黏附分子 1 在非酒精性脂肪性肝病中的作用。

Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease.

机构信息

Division of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Department of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.

Diabetes Center, Faculty of Medicine, Geneva University, 1205 Geneva, Switzerland.

出版信息

Int J Mol Sci. 2023 Jul 10;24(14):11271. doi: 10.3390/ijms241411271.

DOI:10.3390/ijms241411271
PMID:37511031
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10379080/
Abstract

Nonalcoholic fatty liver disease (NAFLD) has become a widely studied subject due to its increasing prevalence and links to diseases such as type 2 diabetes and obesity. It has severe complications, including nonalcoholic steatohepatitis, cirrhosis, hepatocellular carcinoma, and portal hypertension that can lead to liver transplantation in some cases. To better prevent and treat this pathology, it is important to understand its underlying physiology. Here, we identify two main factors that play a crucial role in the pathophysiology of NAFLD: oxidative stress and the key role of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). We discuss the pathophysiology linking these factors to NAFLD pathophysiology.

摘要

非酒精性脂肪性肝病(NAFLD)因其发病率的增加以及与 2 型糖尿病和肥胖等疾病的关联而成为一个广泛研究的课题。它有严重的并发症,包括非酒精性脂肪性肝炎、肝硬化、肝细胞癌和门脉高压,在某些情况下可能导致肝移植。为了更好地预防和治疗这种病理,了解其潜在的生理学机制非常重要。在这里,我们确定了两个在 NAFLD 病理生理学中起关键作用的主要因素:氧化应激和癌胚抗原相关细胞黏附分子 1(CEACAM1)的关键作用。我们讨论了将这些因素与 NAFLD 病理生理学联系起来的病理生理学机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f536/10379080/7c1ac639b10a/ijms-24-11271-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f536/10379080/2aebf4ab4be8/ijms-24-11271-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f536/10379080/7c1ac639b10a/ijms-24-11271-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f536/10379080/2aebf4ab4be8/ijms-24-11271-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f536/10379080/7c1ac639b10a/ijms-24-11271-g002.jpg

相似文献

1
Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease.氧化应激和癌胚抗原相关细胞黏附分子 1 在非酒精性脂肪性肝病中的作用。
Int J Mol Sci. 2023 Jul 10;24(14):11271. doi: 10.3390/ijms241411271.
2
Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).非酒精性脂肪性肝病(NAFLD)/非酒精性脂肪性肝炎(NASH)的分子机制。
Adv Exp Med Biol. 2021;1261:223-229. doi: 10.1007/978-981-15-7360-6_20.
3
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.非酒精性脂肪性肝病、代谢风险因素与肝细胞癌:一个悬而未决的问题。
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
4
MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.微小 RNA 在非酒精性脂肪性肝病发病机制中的作用。
Int J Biol Sci. 2021 Apr 29;17(7):1851-1863. doi: 10.7150/ijbs.59588. eCollection 2021.
5
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?代谢综合征与非酒精性脂肪性肝病:胰岛素抵抗是其中的关联因素吗?
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:55-65. doi: 10.1016/j.mce.2015.02.018. Epub 2015 Feb 24.
6
Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.微量营养素抗氧化剂与非酒精性脂肪性肝病
Int J Mol Sci. 2016 Aug 23;17(9):1379. doi: 10.3390/ijms17091379.
7
Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.非酒精性脂肪性肝病与代谢综合征的相互作用。
Obes Rev. 2019 Apr;20(4):599-611. doi: 10.1111/obr.12820. Epub 2018 Dec 27.
8
[NAFLD pathogenesis in the light of recent research].基于近期研究的非酒精性脂肪性肝病发病机制
Postepy Biochem. 2017;63(3):190-197.
9
Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.针对代谢、胰岛素抵抗和糖尿病治疗非酒精性脂肪性肝炎。
Diabetes. 2018 Dec;67(12):2485-2493. doi: 10.2337/dbi18-0024.
10
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!新型抗糖尿病药物对非酒精性脂肪肝和脂肪性肝炎的影响:另辟蹊径!
Metabolism. 2019 Dec;101:154001. doi: 10.1016/j.metabol.2019.154001. Epub 2019 Oct 28.

引用本文的文献

1
Tacrolimus (FK506) promotes placentation and maternal-fetal tolerance through modulating FASN-CEACAM1 pathway.他克莫司(FK506)通过调节脂肪酸合酶-癌胚抗原相关细胞黏附分子1(FASN-CEACAM1)通路促进胎盘形成和母胎耐受。
Front Immunol. 2025 Feb 19;16:1522346. doi: 10.3389/fimmu.2025.1522346. eCollection 2025.
2
Identifying CEACAM1 as a potential prognostic biomarker for basal-like breast cancer by bioinformatics analysis and experiments.通过生物信息学分析和实验确定癌胚抗原相关细胞黏附分子1(CEACAM1)作为基底样乳腺癌的潜在预后生物标志物。
J Cancer. 2024 Oct 21;15(19):6468-6478. doi: 10.7150/jca.101636. eCollection 2024.
3
Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma.

本文引用的文献

1
Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model.司美格鲁肽改善非酒精性脂肪性肝病小鼠模型的代谢和肝脏结局。
Front Endocrinol (Lausanne). 2022 Dec 9;13:1046130. doi: 10.3389/fendo.2022.1046130. eCollection 2022.
2
Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology.1 型糖尿病中非酒精性脂肪性肝病:患病率和病理生理学。
Front Endocrinol (Lausanne). 2022 Dec 1;13:1031633. doi: 10.3389/fendo.2022.1031633. eCollection 2022.
3
Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
利用基于性别的生物标志物和药物靶点:推进肝细胞癌的个性化治疗策略
Front Pharmacol. 2024 Jun 20;15:1433540. doi: 10.3389/fphar.2024.1433540. eCollection 2024.
每周一次皮下注射司美格鲁肽可改善 2 型糖尿病患者的脂肪肝疾病:一项为期 52 周的前瞻性真实世界研究。
Nutrients. 2022 Nov 4;14(21):4673. doi: 10.3390/nu14214673.
4
Insulin Clearance in Health and Disease.胰岛素在健康与疾病中的清除
Annu Rev Physiol. 2023 Feb 10;85:363-381. doi: 10.1146/annurev-physiol-031622-043133. Epub 2022 Oct 19.
5
NAFLD: From Mechanisms to Therapeutic Approaches.非酒精性脂肪性肝病:从发病机制到治疗方法
Biomedicines. 2022 Jul 20;10(7):1747. doi: 10.3390/biomedicines10071747.
6
When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD.当糖到达肝脏时:糖尿病和非酒精性脂肪性肝病患者的表型
J Clin Med. 2022 Jun 8;11(12):3286. doi: 10.3390/jcm11123286.
7
NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook.烟酰胺腺嘌呤二核苷酸磷酸氧化酶与脂肪性肝病、胰岛素抵抗和2型糖尿病的关联:当前认知与治疗展望
Antioxidants (Basel). 2022 Jun 9;11(6):1131. doi: 10.3390/antiox11061131.
8
Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes.非酒精性脂肪性肝病:1型和2型糖尿病患者相同的病因因素
Eur J Intern Med. 2022 Jun;100:77-82. doi: 10.1016/j.ejim.2022.03.025. Epub 2022 Apr 3.
9
Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review.脂肪组织解剖位置、细胞表型和灌注在中间代谢中的作用:叙事性综述。
Rev Endocr Metab Disord. 2022 Feb;23(1):43-50. doi: 10.1007/s11154-021-09708-3. Epub 2022 Jan 15.
10
NAFLD in type 1 diabetes: overrated or underappreciated?1型糖尿病中的非酒精性脂肪性肝病:被高估还是被低估?
Ther Adv Endocrinol Metab. 2021 Nov 23;12:20420188211055557. doi: 10.1177/20420188211055557. eCollection 2021.